Table 2. Treatment of children with OMS-NB (N=14).

Patient No.	Gender	Age at OMS onset (months)	Stage (INRG)	Immune therapy	Tumor resection	Course of chemotherapy
						Pre-operative	Post-operativea
1	Male	20	L1	I, M	CR	0	3
2	Male	27	L1	M, P	CR	0	0
3	Female	16	L1	I, A, M, R	CR	0	4
4	Male	54	L2	P	CR	0	10
5	Female	13	L2	–	CR	1	6
6	Female	24	L1	–	MRD	0	0
7	Male	19	L2	–	CR	0	6
8	Male	16	L2	I	CR	4	6
9	Male	21	L1	I, P	CR	0	6
10	Female	24	L1	I, M, P	CR	2	0
11	Male	39	L2	–	CR	4	8
12	Male	14	L2	I	CR	2	4
13	Female	18	L2	I, P	MRD	2	3
14	Male	22	L1	I, P	CR	1	2

^a, the courses of post-operative chemotherapy were counted before relapse if the patient suffered relapse. OMS, opsoclonus myoclonus syndrome; NB, neuroblastoma; INRG, International Neuroblastoma Risk Group; CR, complete resection; MRD, microscopic residual disease; M, methylprednisolone; I, intravenous immunoglobulin; P, prednisone; A, adrenocorticotropic hormone; R, rituximab.